Novartis Ag (NVS) Debt Ratio (2009 - 2026)

Novartis Ag (NVS) posted Debt Ratio of 0.39 for Q2 2026, up 27.62% sequentially from 0.3 in Q4 2025, and up 30.82% YoY from 0.29 in Q2 2025.

Novartis Ag (NVS) Debt Ratio (2009 - 2026) Analysis & Trends

Novartis Ag has reported Debt Ratio for 18 years, with the latest figure at 0.39 in Q2 2026.

Quarterly Debt Ratio rose 30.82% year-over-year to 0.39 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 0.39 (up 30.82% YoY) and the FY2025 annual result came in at 0.3, up 4.42% from the prior year.
Debt Ratio advanced to 0.39 in Q2 2026 per NVS's latest filing, from 0.3 in the prior quarter.
Over five years, Debt Ratio peaked at 0.39 in Q2 2026 and troughed at 0.21 in Q4 2024.
A 5-year average of 0.27 and a median of 0.25 in 2023 frame the typical range for Debt Ratio.
The sharpest annual moves came in 2024 and 2025: Debt Ratio dropped 15.18% in 2024, then soared 44.72% in 2025.
Over 5 years, Debt Ratio stood at 0.22 in 2022, then gained by 10.5% to 0.25 in 2023, then dropped by 15.18% to 0.21 in 2024, then jumped by 44.72% to 0.3 in 2025, then advanced by 27.62% to 0.39 in 2026.
According to Business Quant data, Debt Ratio over the past three periods registered 0.39, 0.3, and 0.29 for Q2 2026, Q4 2025, and Q2 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Johnson & Johnson	645.88 Bn	625.12 Bn	17.26 Bn	0.24
2	AbbVie	463.46 Bn	456.89 Bn	12.70 Bn	0.52
3	Merck	367.92 Bn	360.78 Bn	12.21 Bn	0.42
4	Novartis Ag	297.71 Bn	290.02 Bn	11.24 Bn	0.08
5	Astrazeneca	255.55 Bn	250.65 Bn	12.86 Bn	0.25
6	Amgen	234.52 Bn	220.53 Bn	7.24 Bn	0.66
7	Gilead Sciences	178.22 Bn	175.04 Bn	6.22 Bn	0.58
8	Pfizer	158.57 Bn	146.88 Bn	10.94 Bn	0.31
9	Gsk	105.32 Bn	101.15 Bn	8.24 Bn	-0.31
10	Sanofi	54.20 Bn	46.82 Bn	10.79 Bn	0.17

Download Data